GOVX

GeoVax Labs, Inc.

$0.11

-22.03%
SectorHealthcareIndustryBiotechnologyCountryUnited States
OverviewAI BriefChartFinancialsExposureFilingsScoresNewsAnalystsInsidersOwnership

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Source: Yahoo Finance
Q-Score—/ 100
Market Cap$1.1M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
AnalystsBuy+8868.6% target
Beta1.61
AI summary

Price & performance

1M-42.7%
3M-73.5%
YTD-96.1%
1Y-98.6%
52-week range—
Beta1.61
Full chart and returns against a benchmark

Q-Score

—/ 100

Quality against peers; 50 is the peer median.

Growth16
Risk24
Performance15
Valuation—
Profitability—
Leverage49
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$2.5M-37.1%
Net income-$21.5M
Net margin-862.3%-230.4 pts
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtApr 15, 2026
Late filing noticeMar 31, 2026
Exchange listing noticeAug 28, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

GOVXIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.646.22PEG—4.02
Dividend yield0.00%
Every valuation metric